RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dongkook Pharmaceutical Co Stock

Dongkook Pharmaceutical Co EBIT 2024

Dongkook Pharmaceutical Co EBIT

80.87 B KRW

Ticker

086450.KQ

ISIN

KR7086450004

In 2024, Dongkook Pharmaceutical Co's EBIT was 80.87 B KRW, a 20.93% increase from the 66.87 B KRW EBIT recorded in the previous year.

The Dongkook Pharmaceutical Co EBIT history

YEAREBIT (undefined KRW)
2026e105.39
2025e92.79
2024e80.87
202366.87
202272.65
202163.22
202084.73
201968.59
201855.12
201750.07
201646.93
201533.61
201426.55
201324.52
201227.06

Dongkook Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Dongkook Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Dongkook Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Dongkook Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Dongkook Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Dongkook Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Dongkook Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Dongkook Pharmaceutical Co’s growth potential.

Dongkook Pharmaceutical Co Revenue, EBIT and net profit per share

DateDongkook Pharmaceutical Co RevenueDongkook Pharmaceutical Co EBITDongkook Pharmaceutical Co Net Income
2026e969.75 B undefined105.39 B undefined69.41 B undefined
2025e894.22 B undefined92.79 B undefined73.33 B undefined
2024e814.73 B undefined80.87 B undefined88.37 B undefined
2023730.99 B undefined66.87 B undefined47.18 B undefined
2022661.65 B undefined72.65 B undefined52.9 B undefined
2021594.19 B undefined63.22 B undefined50.35 B undefined
2020559.1 B undefined84.73 B undefined55.93 B undefined
2019482.28 B undefined68.59 B undefined56.31 B undefined
2018400.81 B undefined55.12 B undefined46.95 B undefined
2017354.77 B undefined50.07 B undefined39.6 B undefined
2016309.69 B undefined46.93 B undefined40.66 B undefined
2015259.93 B undefined33.61 B undefined27.43 B undefined
2014226.01 B undefined26.55 B undefined21.1 B undefined
2013213.09 B undefined24.52 B undefined16.76 B undefined
2012180.3 B undefined27.06 B undefined22.31 B undefined

Dongkook Pharmaceutical Co stock margins

The Dongkook Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Dongkook Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Dongkook Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Dongkook Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Dongkook Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Dongkook Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Dongkook Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Dongkook Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Dongkook Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Dongkook Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Dongkook Pharmaceutical Co Margin History

Dongkook Pharmaceutical Co Gross marginDongkook Pharmaceutical Co Profit marginDongkook Pharmaceutical Co EBIT marginDongkook Pharmaceutical Co Profit margin
2026e56.19 %10.87 %7.16 %
2025e56.19 %10.38 %8.2 %
2024e56.19 %9.93 %10.85 %
202356.19 %9.15 %6.45 %
202257.41 %10.98 %7.99 %
202158.95 %10.64 %8.47 %
202060.35 %15.16 %10 %
201960.3 %14.22 %11.68 %
201859.37 %13.75 %11.71 %
201759.01 %14.11 %11.16 %
201659.06 %15.15 %13.13 %
201557.07 %12.93 %10.55 %
201456.62 %11.75 %9.33 %
201357.71 %11.51 %7.87 %
201258.97 %15.01 %12.38 %

Dongkook Pharmaceutical Co Aktienanalyse

What does Dongkook Pharmaceutical Co do?

Dongkook Pharmaceutical Co Ltd is a South Korean company that specializes in the development and manufacturing of pharmaceutical products. It was founded in 1968 by Choon-kyu Kim, who was working in the research department of Pfizer at the time and wanted to start his own company. During the early years, Dongkook focused on the formulation of drugs and medications manufactured by other companies. In the 1980s, Dongkook expanded its business and started developing and manufacturing its own products. A new facility was also built in Bucheon, a suburb of Seoul, during this time. Production focused on prescription medications, particularly cardiovascular drugs and antidiabetic agents. Dongkook became one of the leading companies in South Korea in this area. In the 1990s, Dongkook continued its expansion and began focusing on the Asian market. New markets were tapped into and partnerships with other pharmaceutical companies were established. In 2000, Dongkook went public, providing additional capital. Today, Dongkook is a globally operating company with a wide portfolio of medications and healthcare products. The company is divided into various business segments, including cardiovascular, diabetes, gastrointestinal, and dermatology. Each of these segments encompasses a wide range of products, from prescription drugs to over-the-counter dietary supplements. In the cardiovascular segment, Dongkook offers pharmaceuticals for the treatment of conditions such as heart failure, hypertension, and angina pectoris. The diabetes segment includes medications for the treatment of type 2 diabetes and other metabolic disorders. In the gastrointestinal segment, Dongkook produces medications for the treatment of stomach and intestinal problems, as well as for supporting the digestive system. In dermatology, the company manufactures medications for the treatment of skin diseases and cosmetic products. An important focus of Dongkook is the research and development of new innovative products. The company has its own research and development department, where work is done on new medications and technologies. Through close collaboration with other companies and research institutions around the world, Dongkook has been able to develop numerous products that are distinguished by their high quality and effectiveness. Dongkook is also committed to promoting sustainable and environmentally friendly business practices. The company is dedicated to the use of renewable energies and continuously works on measures to reduce its environmental impact. Additionally, the company is an active member of the community and supports numerous social initiatives, such as donation campaigns for non-profit organizations, educational programs, and environmental conservation projects. In summary, Dongkook Pharmaceutical Co Ltd is a leading global pharmaceutical company known for its innovation, product quality, and sustainable business practices. With a wide portfolio of medications and healthcare products, as well as a strong research and development department, the company is well-positioned for the future and will continue to play an important role in the pharmaceutical industry. Dongkook Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Dongkook Pharmaceutical Co's EBIT

Dongkook Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Dongkook Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Dongkook Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Dongkook Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Dongkook Pharmaceutical Co stock

How much did Dongkook Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Dongkook Pharmaceutical Co has achieved an EBIT of 80.87 B KRW.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Dongkook Pharmaceutical Co.

How has the EBIT of Dongkook Pharmaceutical Co developed in recent years?

The EBIT of Dongkook Pharmaceutical Co has increased by 20.926% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Dongkook Pharmaceutical Co?

The EBIT of Dongkook Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Dongkook Pharmaceutical Co pay?

Over the past 12 months, Dongkook Pharmaceutical Co paid a dividend of 180 KRW . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, Dongkook Pharmaceutical Co is expected to pay a dividend of 196.06 KRW.

What is the dividend yield of Dongkook Pharmaceutical Co?

The current dividend yield of Dongkook Pharmaceutical Co is 1.03 %.

When does Dongkook Pharmaceutical Co pay dividends?

Dongkook Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Dongkook Pharmaceutical Co?

Dongkook Pharmaceutical Co paid dividends every year for the past 15 years.

What is the dividend of Dongkook Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 196.06 KRW are expected. This corresponds to a dividend yield of 1.12 %.

In which sector is Dongkook Pharmaceutical Co located?

Dongkook Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dongkook Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dongkook Pharmaceutical Co from 4/19/2024 amounting to 180 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did Dongkook Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 4/19/2024.

What was the dividend of Dongkook Pharmaceutical Co in the year 2023?

In the year 2023, Dongkook Pharmaceutical Co distributed 180 KRW as dividends.

In which currency does Dongkook Pharmaceutical Co pay out the dividend?

The dividends of Dongkook Pharmaceutical Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Dongkook Pharmaceutical Co

Our stock analysis for Dongkook Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dongkook Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.